Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 3/20 | 0.40 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.39 |
| ▸ | MYLK | Q15746 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8319222 | 1.00 | SIGMAR1 (0.44) | SIGMAR1DRD2DRD4HTR2AHTR2C | |
| SCHEMBL8655046 | 0.93 | SIGMAR1 (0.41) | SIGMAR1DRD2DRD4HTR2AHTR2C | |
| SCHEMBL8657832 | 0.89 | SIGMAR1 (0.45) | SIGMAR1DRD2DRD4HTR2AHTR2C | |
| SCHEMBL8656217 | 0.88 | SIGMAR1 (0.42) | SIGMAR1HTR2AHTR2CPRKCEMYLK | |
| SCHEMBL8655471 | 0.88 | DRD2 (0.38) | SIGMAR1DRD2DRD4HTR2AHTR2C | |
| SCHEMBL8657684 | 0.84 | HTR2A (0.46) | DRD2DRD4HTR2AHTR2C | |
| SCHEMBL8448934 | 0.81 | HTR2A (0.40) | SIGMAR1HTR2AHTR2CPRKCEMYLK | |
| SCHEMBL1999141 | 0.81 | HTR2A (0.40) | SIGMAR1HTR2AHTR2CPRKCEMYLK | |
| SCHEMBL8449854 | 0.80 | SIGMAR1 (0.49) | SIGMAR1HTR2AHTR2CPRKCEMYLK | |
| SCHEMBL8324461 | 0.79 | HTR2A (0.48) | SIGMAR1HTR2AHTR2CPRKCEMYLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7049312-B1 | Benzothiazinone and benzoxazinone compounds | ABBOTT GMBH & CO. KG (DE) | 2006-05-23 | — | — | US | disclosed |
| US-20030134886-A1 | Pharmaceutically active compounds | ASTRAZENECA AB, A SWEDISH CORPORATION | 2003-07-17 | — | — | US | disclosed |
| US-6492409-B1 | SUCH AS 5-(1-(3-AMINOPROPYL)-3-INDOLYL)-1-(3-INDOLYL)-1,3-DIHYDROIMIDAZOL-2-ONE; PROTEIN KINASE C INHIBITORS; HIGH SOLUBILITY; REDUCED COLOR; TREATING INFLAMMATORY AND/OR IMMUNOLOGICAL DISORDERS | ASTRAZENECA AB (SE) | 2002-12-10 | — | — | US | disclosed |
| EP-1192150-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | AstraZeneca AB (SE) | 2002-04-03 | — | — | EP | disclosed |
| EP-1181282-A2 | BENZOTHIAZINONE AND BENZOXAZINONE COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000078750-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-12-28 | — | — | WO | disclosed |
| WO-2000075139-A2 | BENZOTHIAZINONE AND BENZOXAZINONE COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2000-12-14 | — | — | WO | disclosed |
| US-5721245-A | ANTIINFLAMMATORY AGENTS, RESPIRATORY SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1998-02-24 | — | — | US | disclosed |
| EP-0540956-B1 | Process for the manufacture of substituted maleimides | HOFFMANN LA ROCHE (CH) | 1997-09-03 | — | — | EP | disclosed |
| US-5399712-A | Protein kinase C inhibitor | HOFFMANN-LA ROCHE INC. (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0384349-B1 | Substituted pyrroles | HOFFMANN LA ROCHE (CH) | 1994-04-27 | — | — | EP | disclosed |
| EP-0540956-A1 | Process for the manufacture of substituted maleimides | F. HOFFMANN-LA ROCHE AG (CH) | 1993-05-12 | — | — | EP | disclosed |
| EP-0384349-A1 | Substituted pyrroles | F. HOFFMANN-LA ROCHE AG (CH) | 1990-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134886-A1 | Pharmaceutically active compounds | HTR3C, HTR6, CNR1 | SIGMAR1 78/4885DRD2 676/4885DRD4 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.